Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 18, 1988 - Issue 2
8
Views
5
CrossRef citations to date
0
Altmetric
Original Article

The use of single sample clearance estimates to probe hepatic drug metabolism in rats. I

, , &
Pages 151-159 | Received 11 Feb 1987, Published online: 30 Sep 2009

References

  • Bachmann K. Screening for the influence of host factors on warfarin clearance using a single dose, single sample procedure. International Journal of Clinical Pharmacology Therapy and Toxicology 1986; 24: 167–170
  • Bachmann K. Estimating the clearance of amylobarbitone from a single plasma measurement. British Journal of Clinical Pharmacology 1987; 23: 94–98
  • Bachmann K., Schwartz J., Forney R., Jr., Jauregui L. Theophylline kinetics: dose dependency and single sample prediction of clearance. Pharmacology 1985a; 30: 136–144
  • Bachmann K., Schwartz J., Forney R., Jr., Jauregui L. Phenytoin as a probe of drug metabolism: predicting clearance with a salivary sample. Pharmacology 1985b; 30: 145–152
  • Bachmann K., Schwartz J., Sullivan T., Jauregui L. Single sample estimate of ethosuximide clearance. International Journal of Clinical Pharmacology Therapy and Toxicology 1986; 10: 546–550
  • Dandliker W., Kelly R. Fluorescence polarization immunoassay: Theory and experimental method. Immunochemistry 1973; 10: 219–227
  • Dossing M. Changes in hepatic microsomal enzyme function in workers exposed to mixtures of chemicals. Clinical Pharmacology and Therapeutics 1982; 32: 340–346
  • Dossing M., Poulsen H., Andreasen P. B., Tygstrup N. A simple method for determination of antipyrine clearance. Clinical Pharmacology and Therapeutics 1982; 32: 392–396
  • Dossing M., Skinhoj P. Occupational liver injury: Present state of knowledge and further perspective. International Archives for Occupational and Environmental Health 1985; 56: 1–21
  • Dossing M., Volund A., Poulsen H. Optimal sampling times for minimum variance of clearance determination. British Journal of Clinical Pharmacology 1983; 15: 231–235
  • Iversen P., Franklin M. Microsomal cytochrome P-450 ‘handprints’: Five fractions from anion-exchange high-pressure liquid chromatography provide a rapid preliminary screen for selectivity in the induction and destruction of rat hepatic cytochrome P-450 subpopulations. Toxicology and Applied Pharmacology 1985; 78: 1–9
  • Jolley M. Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. Journal of Analytical Toxicology 1981; 5: 236–240
  • Jusko W. J. Guidelines for collection and analysis of pharmacokinetic data. Applied Pharmacokinetics, W. Evans, J. Schentag, W. J. Jusko. Applied Therapeutics, Spokane 1986; 9–54
  • Pilsgaard H., Poulsen H. A one sample method for antipyrine clearance determination in rats. Pharmacology 1984; 29: 110–116
  • Sheiner L., Beal S. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9: 503–512
  • Slattery J., Gibaldi M., Koup J. Prediction of maintenance dose required to attain a desired drug concentration at steady-state from a single determination of concentration after an initial dose. Clinical Pharmacokinetics 1980; 5: 377–385
  • Sonne J., Dossing M., Loft S., Andreasen P. B. Antipyrine clearance in pneumonia. Clinical Pharmacology and Therapeutics 1985; 37: 701–704
  • Ueland P., Kvalheim G., Lonning P., Kvinnsland S. Determination of warfarin in human plasma by high performance liquid chromatography and photodiode array detector. Therapeutic Drug Monitoring 1985; 7: 329–335
  • Umeda T., Inaba T. Effects of anaesthetics on diphenylhydantoin metabolism in the rat: possible inhibition by diethyl ether. Canadian Journal of Physiology and Pharmacology 1978; 56: 241–244
  • Van DER Graaff M., Vermeulen N., Heij P., De Bree H., Breimer D. Correlation between the metabolism of hexobarbital and aminopyrine in vivo in rats. Xenobiotica 1986; 16: 1091–1096
  • Vesell E. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 1979; 26: 275–286

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.